Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Identification of Anti-Lymphoma Biomarkers of Response to the Anti-CD37 Antibody Drug Conjugate (ADC) IMGN529

Eugenio Gaudio, PhD, Chiara Tarantelli, PhD, Alberto Arribas, PhD, Luciano Cascione, PhD, Ivo Kwee, PhD, Andrea Rinaldi, PhD, Maurilio Ponzoni, MD, Roberta Pittau Bordone, Georg Stussi, MD, Davide Rossi, MD PhD, Emanuele Zucca, Anastasios Stathis, Callum Sloss, PhD Molecular Biology, Francesco Bertoni, MD

Blood (2016) 128 (22): 4187.

https://doi.org/10.1182/blood.V128.22.4187.4187

Published: 2016

Journal Articles

Ninlaro (ixazomib) and Brentuximab Vedotin (ADCETRIS) Combination Results in Synergistic Antitumor Activity in Mouse Models of CD30 Positive Anaplastic Large Cell Lymphoma

Nibedita Chattopadhyay, PhD, Sakeena Syed, Yuhong Zhang, Jie Yu, M.S., Dan He McDougall, Lunyin Yu Yu, Stephen Tirrell, PhD, Allison Berger, PhD, Helgi van de Velde, MD PhD, Christopher Tremblay, Dirk Huebner, MD

Blood (2016) 128 (22): 1842.

https://doi.org/10.1182/blood.V128.22.1842.1842

Published: 2016

Journal Articles

Evaluation of Patient-Derived Xenografts for Modeling Outcome of Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

Abdulmohsen M Alruwetei, Msc, Hernan Carol, PhD, Rosemary Sutton, PhD, Glenn M Marshall, MBBS, MD FRACP, Richard B Lock, PhD

Blood (2015) 126 (23): 3759.

https://doi.org/10.1182/blood.V126.23.3759.3759

Published: 2015

Journal Articles

Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL),

Andres Forero-Torres, MD, R. Brian Berryman, MD, Ranjana H. Advani, MD, Nancy L. Bartlett, MD, Robert W. Chen, MD, Michelle A. Fanale, MD, Ajay K. Gopal, MD, Owen A. O'Connor, MD, PhD, Randal Olshefski, MD, Scott E. Smith, MD, PhD, FACP, Laurie E. Grove, PA-C, Jeffrey Matous, MD

Blood (2011) 118 (21): 3711.

https://doi.org/10.1182/blood.V118.21.3711.3711

Published: 2011

Journal Articles

Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update

Ranjana H. Advani, MD, Andrei R. Shustov, MD, Pauline Brice, MD, Nancy L. Bartlett, MD, Joseph D. Rosenblatt, MD, Tim Illidge, MD, Jeffrey Matous, MD, Radhakrishnan Ramchandren, Michelle A. Fanale, MD, Joseph M. Connors, MD, Yin Yang, MS, Dana A. Kennedy, PharmD, Barbara Pro, MD

Blood (2011) 118 (21): 443.

https://doi.org/10.1182/blood.V118.21.443.443

Published: 2011

Journal Articles

Activity of the Investigational Antibody–Drug Conjugate Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large-Cell Lymphoma: Comparisons with Meta-Analyses of Historical Control Chemotherapy Data

Antonio Gualberto, MD, PhD, Andy Chi, MD, PhD, Yi Liu, PhD

Blood (2011) 118 (21): 4975.

https://doi.org/10.1182/blood.V118.21.4975.4975

Published: 2011

Journal Articles

Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas

Tim Illidge, Reda Bouabdallah, MD, Robert W. Chen, MD, Ajay K. Gopal, MD, Craig H. Moskowitz, MD, Radhakrishnan Ramchandren, Joseph D. Rosenblatt, MD, Andrei R. Shustov, MD, Herve Tilly, MD, Tanya Trippett, MD, Laurie E. Grove, PA-C, Ranjana H. Advani, MD

Blood (2011) 118 (21): 3091.

https://doi.org/10.1182/blood.V118.21.3091.3091

Published: 2011

Journal Articles

Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma

Anas Younes, MD, Joseph M. Connors, MD, Steven I. Park, MD, Naomi N.H. Hunder, MD, Stephen M. Ansell, MD, PhD

Blood (2011) 118 (21): 955.

https://doi.org/10.1182/blood.V118.21.955.955

Published: 2011

Journal Articles

Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Andrei R. Shustov, MD, Ranjana Advani, MD, Pauline Brice, MD, Nancy L. Bartlett, MD, Joseph D. Rosenblatt, MD, Tim Illidge, MD, Jeffrey Matous, MD, Radhakrishnan Ramchandren, MD, Michelle A. Fanale, MD, Joseph M. Connors, MD, Yin Yang, MS, Eric L. Sievers, MD, Dana A. Kennedy, PharmD, Barbara Pro, MD

Blood (2010) 116 (21): 961.

https://doi.org/10.1182/blood.V116.21.961.961

Published: 2010

Journal Articles

Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma

Robert Chen, Ajay K. Gopal, MD, Scott E. Smith, MD, PhD, FACP, Stephen M. Ansell, MD, PhD, Joseph D. Rosenblatt, MD, Richard Klasa, MD, CM, FRCP(C), Joseph M. Connors, MD, Andreas Engert, MD, Emily K. Larsen, MS, Dana A. Kennedy, PharmD, Eric L. Sievers, MD, Anas Younes, MD

Blood (2010) 116 (21): 283.

https://doi.org/10.1182/blood.V116.21.283.283

Published: 2010

Journal Articles

Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EM011

Ritu Aneja, Jun Zhou, Surya N. Vangapandu, Binfei Zhou, Ramesh Chandra, Harish C. Joshi

Blood (2006) 107 (6): 2486–2492.

https://doi.org/10.1182/blood-2005-08-3516

Published: 2006

NARROW

Identification of Anti-Lymphoma Biomarkers of Response to the Anti-CD37 Antibody Drug Conjugate (ADC) IMGN529

Ninlaro (ixazomib) and Brentuximab Vedotin (ADCETRIS) Combination Results in Synergistic Antitumor Activity in Mouse Models of CD30 Positive Anaplastic Large Cell Lymphoma

Evaluation of Patient-Derived Xenografts for Modeling Outcome of Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL),

Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update

Activity of the Investigational Antibody–Drug Conjugate Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large-Cell Lymphoma: Comparisons with Meta-Analyses of Historical Control Chemotherapy Data

Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas

Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma

Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma

Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EM011

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only